7th Circ. Won't Revive Claims Of 1,000 Pfizer Suits In MDL
By Diana Novak Jones (January 19, 2018, 9:17 PM EST) -- The Seventh Circuit on Friday declined to revive claims in more than 1,000 lawsuits against Pfizer Inc. included in the multidistrict litigation for testosterone replacement therapy drugs, finding the suits' state law claims about the company's drug Depo-Testosterone were preempted by federal drug regulations.
The appellate court agreed with the district court judge overseeing the MDL that Pfizer was barred from changing the label on Depo-Testosterone to include additional warnings by FDA regulations governing generic-drug makers and a U.S. Supreme Court decision interpreting them. Therefore, the plaintiffs' state law claims that the company had failed to warn patients about Depo-Testosterone users'...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!